DBV Technologies S.A. ADR (DBVT)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Daniel Tassé
Employees:
90
177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, FRANCE 92120
33(0)155427878

DBV Technologies S.A. engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus.

Data derived from most recent annual or quarterly report
Market Cap 154.266 Million Shares Outstanding110.19 Million Avg 30-day Volume 211.134 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue18.3033 Debt to Equity0.0 EBITDA-71.742 Million
Price to Book Value0.7838 Operating Margin-790.0231 Enterprise Value-46.458 Million
Current Ratio7.95 EPS Growth-1.297 Quick Ratio7.491
1 Yr BETA 0.6772 52-week High/Low 3.43 / 1.08 Profit Margin-781.2796
Operating Cash Flow Growth-20.5321 Altman Z-Score1.5586 Free Cash Flow to Firm -30.209 Million
View SEC Filings from DBVT instead.

View recent insider trading info

Funds Holding DBVT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DBVT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-12-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GUYOT-CAPARROS DANIELE

    • Director
    0 2022-10-03 1

    BAKER BROS. ADVISORS LP

    667, L.P.

    BAKER JULIAN

    BAKER FELIX

    BAKER BROS. ADVISORS (GP) LLC

    BAKER BROTHERS LIFE SCIENCES LP

    • Director
    • 10% Owner
    42,508,281 2022-06-13 1

    TASSE DANIEL CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    274,000 2021-11-22 0

    MOHIDEEN PHARIS CHIEF MEDICAL OFFICER

    • Officer
    119,600 2021-11-22 0

    ROBITAILLE SEBASTIEN CHIEF FINANCIAL OFFICER

    • Officer
    79,500 2021-11-22 0

    DE ROSEN MICHEL

    • Director
    6,837 2021-06-10 0

    MORRIS TIMOTHY E

    • Director
    6,837 2021-06-10 0

    SOLAND DANIEL B

    • Director
    6,837 2021-06-10 0

    RAO MADDURI RAVIN

    • Director
    6,837 2021-06-10 0

    MONGES VIVIANE

    • Director
    5,000 2021-06-10 0

    NDU ADORA

    • Director
    6,837 2021-06-10 0

    O'NEILL JULIE

    • Director
    0 2021-01-01 0

    GOLLER MICHAEL

    • Director
    0 2021-01-01 0

    FERRERE MAILYS

    • Director
    0 2021-01-01 0

    BJERKE TORBJORN

    • Director
    35,925 2021-01-01 0

    GIRAUT CLAIRE

    • Director
    0 2021-01-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 22:15:03 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 21:45:03 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 21:15:04 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 20:45:03 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 20:15:04 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 19:45:03 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 19:15:04 UTC -34.9515 39.2715 100000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 18:45:03 UTC -34.9515 39.2715 100000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 18:15:04 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 17:45:04 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 17:15:04 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 16:45:03 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 16:15:04 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 15:45:03 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 15:15:04 UTC -34.9515 39.2715 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 14:45:04 UTC -37.099 41.419 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 14:15:03 UTC -37.099 41.419 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 13:45:03 UTC -37.099 41.419 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 13:15:04 UTC -37.099 41.419 300000
    DBV TECHNOLOGIES SA-SPON ADR DBVT 2023-01-26 12:45:04 UTC -37.099 41.419 300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments